

The FARINGOCAT study: rapid antigen detection testing in acute pharyngitis

Submission date 29/01/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 20/03/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 21/09/2011	Condition category Respiratory	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Montse Balagué Corbella

Contact details
Portaferrissa 8, ppal
Barcelona
Spain
08002

Additional identifiers

Protocol serial number
PI061782

Study information

Scientific Title
Rapid antigen detection testing impact on antibiotic use in acute pharyngitis: FARINGOCAT

Acronym
FARINGOCAT

Study objectives

Rapid antigen detection testing would allow a more rational use of antibiotics and would prevent adverse effects of antibiotics on the patient, antibiotic resistance emergence and the growth of inefficient health expense.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Study approved by the Research Ethics Committee of the Jordi Gol i Gurina Primary Care Research Institute (IDIAP), Barcelona on the 4th July 2006.

Study design

Multicentric randomised clinical assay

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute pharyngitis

Interventions

1. Rapid antigen detection (case group)
2. Usual antigen detection (control group)

Treatment will be decided in both groups by the general practitioner. This treatment could be 'nothing', an anti-thermic drug, anti-inflammatory drug and/or an antibiotic.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

1. Proportion of inadequate antibiotic prescription in each group
2. Use of antibiotic treatment
3. Use of rapid antigen detection testing
4. Rapid antigen detection testing result
5. Culture result

Outcomes will be measured at baseline and three weeks in all patients. If there is a problem, i.e., a secondary effect, then this may take longer.

Key secondary outcome(s)

1. Clinical symptoms of acute pharyngotonsillitis: fever, tonsillar exudate, cervical adenopathies, absence of cough, measured at baseline and at dates below
2. Age, measured at baseline
3. Antibiotic treatment, measured at baseline and at dates below

4. Specific antibiotic treatment, measured at baseline and at dates below
5. Treatment secondary effects, measured at baseline and at dates below
6. Days without working, measured at baseline and at dates below
7. Medical visits during the first month, measured at week three in all patients, at week four if necessary
8. Patient satisfaction, measured between 3 - 4 weeks after the second visit in one group of patients, between 5 - 7 months in another group of patients

Outcomes will be measured at three weeks in all patients. If there is a problem, i.e., a secondary effect, then this may take longer.

Completion date

31/12/2008

Eligibility

Key inclusion criteria

1. Men and women 14 to 60 years old
2. More than one acute pharyngitis symptom, i.e., fever, sore throat, tonsillar exudate, cervical adenopathy and absence of cough, which leads to a visit to the family practice

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

All

Key exclusion criteria

1. Does not consent to participate
2. Patient is younger than 14 or older than 60 years old
3. Pharyngitis more than five times in year
4. Immunodepression: chemotherapy, radiotherapy, active neoplasia, acquired immune deficiency syndrome (AIDS), corticoids, immunosuppressor treatment
5. Valve heart disease
6. Rheumatoid fever
7. Pharyngitis with previous treatment during 15 days or recurrence of symptoms during 4 weeks after 7 days of complete antibiotic treatment
8. Pharyngitis of diphtheria or gonococcal cause
9. Tonsillectomy

Date of first enrolment

01/01/2008

Date of final enrolment

31/12/2008

Locations

Countries of recruitment

Spain

Study participating centre

Portaferrissa 8, ppal

Barcelona

Spain

08002

Sponsor information

Organisation

Jordi Gol i Gurina Primary Care Research Institute (Institut D'Investigació en Atenció Primària) (IDIAP) (Spain)

ROR

<https://ror.org/0370bpp07>

Funder(s)

Funder type

Research organisation

Funder Name

Health Research Fund - Carlos III Health Institute of the Spanish Ministry of Health and Consumption (Fondo de Investigaciones Sanitarias - Instituto de Salud Carlos III-Ministerio de Sanidad y Consumo) (Spain)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2011		Yes	No
Protocol article	protocol	23/03/2010		Yes	No